Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation
01:30am, Tuesday, 21'st Oct 2025
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
04:01pm, Thursday, 16'th Oct 2025
Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective O
Biotechnology firm Galapagos receives offers for cell-therapy business
04:12pm, Wednesday, 01'st Oct 2025
Biotechnology firm Galapagos' board has received non-binding offers from consortia, mainly comprised of financial investors, for its cell-therapy business, the company said on Wednesday.
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business
04:01pm, Wednesday, 01'st Oct 2025
Mechelen, Belgium ; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement:
Galapagos Creates New Subscription Right Plan
04:01pm, Thursday, 07'th Aug 2025
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
04:03pm, Wednesday, 23'rd Jul 2025
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-te
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
04:02pm, Wednesday, 23'rd Jul 2025
New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appoin
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
04:01pm, Wednesday, 23'rd Jul 2025
Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance p
Galapagos Appoints Aaron Cox as Chief Financial Officer
01:30am, Monday, 23'rd Jun 2025
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities
Galapagos Creates New Subscription Right Plan
04:33pm, Tuesday, 27'th May 2025
Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes
01:36am, Tuesday, 13'th May 2025
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments
Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101
06:16pm, Friday, 25'th Apr 2025
Galapagos NV released positive data from the phase 1/2 ATALANTA-1 study using GLPG5101 for the treatment of patients with relapsed/refractory Mantle Cell Lymphoma; 100% ORR/CR was achieved in 8 patien
